No changes were recommended in oral
dosages. The most common uses are for
chemotherapy-induced and post-operative nausea.
Zofran is a commonly used medication for both children and adults
for the treatment of http://www.medicinenet.com/ondansetron-oral/article.htm nausea. Retrieved from http://www.fda.gov/
Wallace J. Electrolyte
abnormalities, particularly hypokalemia and hypomagnesemia should be
corrected prior to administration of Zofran.
Nurse practitioners or others prescribing or administering this
medication need to be aware of these changes.
U.S. Food and Drug Administration. Instead, the current
recommendation is for 0.15 mg/kg every four hours for three doses with
no single dose to exceed 16 Zofran lawsuit mg. (2011). Due to incidents of
prolongation of the QT interval of the ECG following Zofran
administration, the manufacturer, GlaxoSmithKline, was required by the
FDA to conduct a study to assess this particular risk. Prolongation of
the QT interval predisposes the patient to development of a potentially
lethal ventricular tachycardia known as Torsades de Pointes.
As a result of that study, dosage recommendations for the
intravenous form of the medication has been changed. Henkelman, EdD, MSN, RN
Touro University Nevada
COPYRIGHT 2013 Nevada Nurses Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.
. FDA drug safety
communication: New information regarding QT prolongation with
ondansetron (Zofran). Lower dosages used in the treatment of post-operative nausea
are also unchanged.
In addition to the dosage change, caution is recommended in
administration of Zofran to patients with congenital long QT intervals,
patients with congestive heart failure, those with bradyarrhythmias, or
those taking other medications which prolong QT intervals. The previous 32 mg,
single intravenous dose should now be avoided